<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255043</url>
  </required_header>
  <id_info>
    <org_study_id>KY20200110-02</org_study_id>
    <nct_id>NCT04255043</nct_id>
  </id_info>
  <brief_title>Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon</brief_title>
  <acronym>ULTIMATE-III</acronym>
  <official_title>Intravascular Ultrasound Versus Angiography Guided Drug-coated Balloon Treatment for Denovo Lesions in High Bleeding Risk Patients: a Prospective, Multi-center, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-coated balloon (DCB) is an alternative choice for denovo lesions in coronary artery&#xD;
      disease patients with high bleeding risk. Intravascular ultrasound (IVUS) can provide more&#xD;
      details of coronary anatomy and stent implantation, overcoming a number of limitations of&#xD;
      coronary angiography. However, the benefit of IVUS-guided DCB treatment has not been&#xD;
      investigated. This study is designed to compare IVUS-guided and Angiography-guided DCB&#xD;
      treatment for coronary denovo lesions in patients with high bleeding risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized controlled trial that aims to enroll 260&#xD;
      patients with high bleeding risk.&#xD;
&#xD;
      All patients with coronary denovo lesions suitable for DCB treatment will undergo 1:1&#xD;
      randomization to either IVUS guidance or Angiography guidance using the Central Randomization&#xD;
      System.&#xD;
&#xD;
      All subjects will be screened according to the predefined inclusion and exclusion criteria&#xD;
      per protocol. Data and images will be collected during the index procedure, and at the&#xD;
      predefined 7-month coronary angiography follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will undergo 1:1 randomization to either IVUS or Angiography-guided DCB treatment for coronary denovo lesions in patients with high bleeding risk.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor will remain blinded until the final study results released.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss (LLL) at 7 months after procedure</measure>
    <time_frame>7 months</time_frame>
    <description>LLL is defined as the difference between postprocedural minimal lumen diameter (MLD) minus MLD at the time of angiographic follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>TVF is defined as the composite of cardiac death, target-vessel myocardial infarction and ischemia-driven target-vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>IVUS-guided DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided DCB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVUS guidance</intervention_name>
    <description>IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment</description>
    <arm_group_label>IVUS-guided DCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angiography guidance</intervention_name>
    <description>DCB (Sequent® Please) treatment</description>
    <arm_group_label>Angiography-guided DCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. De novo lesions, suitable for DCB treatment.&#xD;
&#xD;
          2. Patients with high bleeding risk.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target lesion length &gt; 15mm.&#xD;
&#xD;
          2. Severe calcified lesions.&#xD;
&#xD;
          3. Left main disease.&#xD;
&#xD;
          4. Ostial lesions.&#xD;
&#xD;
          5. Three-vessel disease.&#xD;
&#xD;
          6. Acute myocardial infarction within 48 hours.&#xD;
&#xD;
          7. Target vessel received stent implantation.&#xD;
&#xD;
          8. Hemodynamic instability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-Jie Zhang, MD</last_name>
    <phone>025-52271350</phone>
    <email>jameszll@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-Fei Gao, MD</last_name>
    <phone>025-52271350</phone>
    <email>gaoxiaofei2014@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Junjie Zhang</investigator_full_name>
    <investigator_title>Vice chief of the department of cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

